論文

査読有り
2017年

Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: Multicentre, randomized, open-label trial

Journal of Antimicrobial Chemotherapy
  • Takuya Sadahira
  • Okayama Urological Research Group (OURG)
  • Koichiro Wada
  • Motoo Araki
  • Ayano Ishii
  • Atsushi Takamoto
  • Yasuyuki Kobayashi
  • Masami Watanabe
  • Toyohiko Watanabe
  • Yasutomo Nasu
  • Hiromi Kumon
  • Teruaki Akaeda
  • Nobuyuki Akazawa
  • Naoki Akebi
  • Daiji Araki
  • Tohru Araki
  • Ryoji Arata
  • Yuichi Ariyoshi
  • Eiichi Ando
  • Nobuyoshi Ando
  • Kazushi Ishii
  • Tsutomu Ishikawa
  • Noritaka Ishito
  • Takaharu Ichikawa
  • Takaaki Inoue
  • Miyabi Inoue
  • Yosuke Inoue
  • Shin Irie
  • Takehiro Iwata
  • Tatsuya Uesugi
  • Shinya Uehara
  • Katsutoshi Uematsu
  • Satoshi Uno
  • Kohei Edamura
  • Shin Ebara
  • Yuko Oiwa
  • Tadashi Oeda
  • Teruhisa Ohashi
  • Yozo Ohashi
  • Hideo Ozawa
  • Junzo Ochi
  • Noriaki Ono
  • Seiji Kai
  • Haruki Kaku
  • Satoshi Katayama
  • Yasuhiro Katayama
  • Tetuzo Kaneshige
  • Keiichiro Kawauchi
  • Masashi Kawaguchi
  • Tatsushi Kawada
  • Taiki Kanbara
  • Mikio Kishi
  • Ryo Kishimoto
  • Nobuyuki Kusaka
  • Norihiro Kusumi
  • Kimito Kunitomi
  • Risa Kubota
  • Hiroaki Kurahashi
  • Hironori Kojima
  • Tomoko Kobayashi
  • Makoto Kobuke
  • Katsuyoshi Kondo
  • Takashi Saika
  • Kazuma Sakaeda
  • Koji Sakuramoto
  • Shinichi Sako
  • Tomoko Sako
  • Taketo Sasaoka
  • Katsumi Sasaki
  • Yoshimasa Jo
  • Morito Sugimoto
  • Yuko Seno
  • Akira Takao
  • Kosuke Takamura
  • Kousuke Takamura
  • Hitoshi Takamoto
  • Katsuji Takeda
  • Tadasu Takenaka
  • Daisuke Tanaka
  • Ryuta Tanimoto
  • Masaya Tsugawa
  • Tomoyasu Tsushima
  • Hiromu Tsuboi
  • Syunji Tojo
  • Kenji Tokinaga
  • Yusuke Tominaga
  • Keisuke Doi
  • Atsushi Nagai
  • Hirochika Nakajima
  • Tetsuya Nakada
  • Hirokazu Nakatsuka
  • Aya Nakamura
  • Yasuki Nakayama
  • Yoshitsugu Nasu
  • Daisuke Nishikawa
  • Jun Nishiguchi
  • Yoshio Nishitani
  • Shingo Nishimura
  • Motoichi Nishimura
  • Yasuhiro Nishiyama
  • Hajime Nibuno
  • Kunihiro Nozaki
  • Hiroyuki Nose
  • Gaku Noda
  • Hideaki Hashimoto
  • Kazuhiro Hata
  • Toshihide Hayashi
  • Nobuki Hayashi
  • Syunji Hayata
  • Ryoei Hara
  • Takeshi Hirata
  • Tomohiro Fujii
  • Kei Fujio
  • Ryuji Fujita
  • Kensuke Bekku
  • Takanori Maehara
  • Yoshio Maki
  • Yuko Matsumoto
  • Daisuke Manabe
  • Yusuke Mayumi
  • Yuki Maruyama
  • Yosuke Mitsui
  • Sadayuki Miyaji
  • Syuhei Munemasa
  • Wataru Murao
  • Takanori Murakami
  • Tadashi Murata
  • Akihiro Mori
  • Akira Morita
  • Koichi Monden
  • Tomoya Yamasaki
  • Masahiro Yamashita
  • Daiduke Yamada
  • Toyoko Yamato
  • Toru Yamane
  • Tomoaki Yamanoi
  • Yasuo Yamamoto
  • Kazuaki Yukari
  • Teruhiko Yokoyama
  • Takashi Yoshioka
  • Yuichi Watanabe
  • 全て表示

72
2
開始ページ
529
終了ページ
534
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1093/jac/dkw424
出版者・発行元
Oxford University Press

Background: Fluoroquinolone-non-susceptible Escherichia coli isolated from patients with acute uncomplicated cystitis are a matter of increasing concern. Cefditoren pivoxil is an oral, β-lactamase-stable, extended-spectrum cephalosporin that is effective against fluoroquinolone-non-susceptible bacteria. Objectives: To evaluate the clinical and microbiological efficacies of cefditoren pivoxil against acute uncomplicated cystitis and to determine the optimal duration of cefditoren pivoxil treatment. Methods: We compared 3 and 7 day regimens of cefditoren pivoxil in a multicentre, randomized, open-label study. Results: A total of 104 female patients with acute uncomplicated cystitis were enrolled and randomized into 3 day (n=51) or 7 day (n=53) treatment groups. At first visit, 94 bacterial strains were isolated from the 104 participants of which 81.7% (85/104) were E. coli. Clinical and microbiological efficacies were evaluated 5-9 days following administration of the final dose of cefditoren pivoxil. The clinical efficacies of the 3 and 7 day groups were 90.9% (40/44) and 93.2% (41/44), respectively (P=1.000). The microbiological efficacies of the 3 and 7 day groups were 82.5% (33/40) and 90.2% (37/41), respectively (P=0.349). There were no adverse events due to cefditoren pivoxil treatment, with the exception of a mild allergic reaction in one patient, after which the cefditoren pivoxil was exchanged for another antimicrobial. Conclusions: Cefditoren pivoxil is safe and effective for uncomplicated cystitis, with no significant differences in clinical and microbiological efficacies between 3 and 7 day regimens.

リンク情報
DOI
https://doi.org/10.1093/jac/dkw424
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/27733519
ID情報
  • DOI : 10.1093/jac/dkw424
  • ISSN : 1460-2091
  • ISSN : 0305-7453
  • PubMed ID : 27733519
  • SCOPUS ID : 85014575637

エクスポート
BibTeX RIS